Nymox Pharmaceutical (Nymox Pharmaceutical) Insider Ownership : 30.33 % (As of May. 15, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nymox Pharmaceutical's insider ownership is 30.33%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nymox Pharmaceutical's Institutional Ownership is 0.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nymox Pharmaceutical's Float Percentage Of Total Shares Outstanding is 56.87%.

Nymox Pharmaceutical Insider Ownership Historical Data

The historical data trend for Nymox Pharmaceutical's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Insider Ownership Chart

Nymox Pharmaceutical Historical Data

The historical data trend for Nymox Pharmaceutical can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	30.99	30.99	30.99	30.33	30.33	30.33	30.33	30.33	30.33	30.33

Nymox Pharmaceutical Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel